Please assess the completion status of the following clinical trial:

Trial Title: Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of CD20 positive chronic lymphocytic leukemia (CLL)~* Either previously untreated or relapsed~* Measurable disease (at least one lesion \> 1.5 cm for NHL, or ALC \> 5,000 for CLL) see full protocol for additional criteria~Exclusion Criteria:~* Previously untreated NHL patients with Stage I and II disease (Ann Arbor classification)~* Previously untreated CLL patients with Stage 0-2 disease (Rai classification) unless specific treatment indications by NCCN guidelines exist (symptomatic, recurrent infections, end-organ function, cytopenias and steady disease progression).~see full protocol for additional criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- veltuzumab (Type: EXPERIMENTAL): veltuzumab is a humanized CD20 antibody administered subcutaneously in this study.

Based on this trial design, predict the completion outcome and termination type (if applicable).